Cimerli
AssetAlso called FYB201
Neutralizes VEGF-A to inhibit abnormal blood vessel growth and vascular leakage.
- Stage
- Approved
- Modality
- Antibody
- Target
- Not known
- 6
- Indications
- 0
- Trials
- 1
- Developer
Approved by the FDA on Aug 2, 2022 (BLA761165). FDA
Indications
63 more
In the full profile
- Owner and partners1
- Competitors12
Every asset’s record: target, stage, trials and the evidence behind it.